NICE Issues Medtech Innovation Briefing on PredictSURE IBD™ for Inflammatory Bowel Disease Prognosis

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has published a Medtech Innovation Briefing (MIB) on the use of PredictSURE IBD„¢ in the prognosis of inflammatory bowel disease.

MIBs are NICE advice designed to support NHS and social care commissioners and staff who are considering using new medical devices and other medical or diagnostic technologies. Designed to be fast, flexible and responsive to the need for information on innovative technologies, MIBs are commissioned by NHS England and produced in support of the NHS 5-Year Forward View, as one of a number of steps to help accelerate innovation in new treatments and diagnostics. Each MIB includes a description of the technology, how it is used, its potential role in the treatment pathway, and the likely cost of using it, as well as a review of relevant published evidence.

PredictSURE IBD„¢ is designed to predict long-term clinical outcomes when Crohns disease or ulcerative colitis are diagnosed, using a gene expression signature identified using quantitative polymerase chain reaction (PCR) technology. Intended to help gastroenterologists choice of treatment for people who have recently been diagnosed with either Crohns disease or ulcerative colitis, evidence evaluated in the MIB shows that PredictSURE IBD„¢ can accurately show which patients are likely to have a severe relapsing disease course.

The evidence also suggests an improved disease response when treatment with tumour necrosis factor (TNF) inhibitors is started early. The MIB reports that the resource impact when using PredictSURE IBD„¢ could be much lower than the current standard of care if starting anti-TNF therapy early leads to disease remission and prevents disease flare ups. However, it must be noted that TNF inhibitors are not currently recommended by NICE for first-line treatment of Crohns disease.

Of the specialist commentators consulted, all agreed that PredictSURE IBD„¢ could improve information to allow clinicians to prescribe more appropriate therapy. A spokesperson for Crohns and Colitis UK, thought the test could change the way patients with Crohns disease are treated by identifying the most effective treatment as early as possible.

Paul Kinnon, CEO, PredictImmune commented: We are very pleased to have received such a positive MIB. Given that these briefings are referenced not only across the UK, but also further afield, it is an important milestone and further validation for us as we continue to develop personalised approaches to treatment for patients with severe, debilitating diseases. We strongly believe that helping to inform clinical decision making in the very early stages of diagnosis could vastly improve patient outcomes and quality of life. The evidence suggests that PredictSURE IBD„¢ enables us to do that for those suffering from Crohns disease and ulcerative colitis, which could have a major impact on treatment pathways in the future.

For information:

Limewash, PR Agency
Sarah Brereton, Director
Tel: +44
(0)1223 813 560